Clarified is a precision medicine company focusing on translating tests into therapy for physicians.

Clarified

Clarified Precision Medicine is the first scalable molecular tumor board with a combination of AI-based platform plus medical group, offering expert clinical somatic and pharmacogenomics consultations through its ClarifiedSelect™ and OncoGuardian™ solutions. Clarified accelerates the delivery of guidelines-based genomic insights to patients and providers by bringing together nationally recognized experts in medical oncology, oncology pharmacy, data integration, and molecular pathology who have over 100 years of collective experience in the application of precision oncology. For more information, visit: www.clarifiedprecisionmedicine.com

Clarified Precision Medicine

Exciting partnership with VieCure and Alabama Cancer Care, demonstrating our joint efforts to deliver better patient care across the board (along with a pretty solid TAT!).

#ICYMI We're thrilled that our joint solution with VieCure is making a significant difference for cancer patients. Thank you Alabama Cancer Care for the opportunity to support your clinicians on their path to more precision medicine!

🌟 Let's talk about impact 🌟 ClarifiedSelect reports are changing the oncologist’s treatment decision for the patient 30% of the time. And with our rapid turnaround time of eight hours or less, we’re bringing nuanced precision medicine insights to each patient 100% of the time. 

Thank you, VieCure and Alabama Cancer Care, for this opportunity to serve ALCC clinicians and patients! I’m very proud that Clarified Precision Medicine is part of this important collaboration, and that we’re already making a significant difference for cancer patients.

You can read more about some of the collaboration’s early results below — we’ll have more to share soon: https://lnkd.in/g6zup8y9

Howard McLeod Chris Gemulla Lisa Alderson April Lynch Lincoln Nadauld Michael Fleming Jody Simon Fred Ashbury PhD MACE

📣 Important news today! 📣 Clarified Precision Medicine and VieCure have just announced that our strategic collaboration is now live at Alabama Cancer Care (ALCC). Our joint solution is successfully deployed in clinical cancer care and already delivering positive results in accelerating the clinical utilization of guidelines-based precision oncology. 
 
One key success factor – Clarified’s response time to referrals is an average of eight hours. This rapid turnaround has been instrumental in supporting the timely utilization of precision medicine at ALCC. 

Get more details on the collaboration’s key achievements in the full announcement >> https://lnkd.in/geS9SbEc 

Thank you, VieCure, for your partnership in a joint solution that is making a significant difference for ALCC patients! 
 
Rajni Natesan, MD, MBA Howard McLeod Lincoln Nadauld Daniel Rotroff Chris Gemulla Lisa Alderson Fred Ashbury PhD MACE Jake Thomas Hailey Hogue    
 
#precisionmedicine #molecularprofiling #precisiononcology #oncology #clarifiedprecisionmedicine #viecure

"Accessibility to genomic tests remains a global challenge." #ICYMI, this insightful and inspiring story from breast cancer patient/physician/scientist Catalina Lopez-Correa (together with a note from our co-founder Lisa Alderson) offers a true call to action to expand access to precision medicine.

➡ Only 3 percent of Stage IV NSCLC patients received targeted therapy. ⬅ 

In this analysis* of more than 39,000 patients with late-stage non-small cell lung cancer, only 22 percent had molecular test results in their medical record, even though guidelines during this period called for testing all such patients for a minimum of three mutations. 

And of those 22 percent, only three percent received targeted therapy – even though targeted therapies have proven improved outcomes in this patient group.**

As the authors in this “US-based real-world data set… .The percentage of patients undergoing testing remains sub-optimal.” This analysis is from 2022, but we know that not enough has yet changed. A key reason for low utilization – challenging, timely interpretations of molecular test results.

Another significant aspect of this study – the authors noted that Causcasians and women were more likely to receive molecular testing than other groups.

Learn more about the study >> https://lnkd.in/gAGk_QPE

This post is part of Clarified’s Journal Club series, where we share important studies in the field of precision medicine and discuss the findings. Please add your thoughts or clinical experiences on this topic in the comments – we’d welcome the chance to keep the dialogue going.

#precisionmedicine #molecularprofiling #precisiononcology #oncology #journalclub #clarifiedprecisionmedicine	

* Journal of Clinical Oncology Meeting Abstract: 2022 ASCO Annual Meeting I
DOI: https://lnkd.in/gAGk_QPE
**Journal of Clinical Oncology 2023, https://lnkd.in/gSmPgW2Q

Metric
Company Name	Clarified
Symbol
MSH ID	COM:CLARIFIEDPRECISIONMEDICINE
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Precision Medicine
Country	US
Stage
Employee Count	9
Website	clarifiedprecisionmedicine.com
LinkedIn	clarifiedprecisionmedicine
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

CLAR

COM:CLARIFIEDPRECISIONMEDICINE

Clarified

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue